Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Amazon Explores AI Content Marketplace With Media Publishers 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
MENLO PARK, Calif., Nov. 15, 2017 -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a leading gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today that company executives will present at upcoming conferences in November.
| Event: | The 29th Annual Piper Jaffray Healthcare Conference | |
| Date: | November 28, 2017 | |
| Time: | 12:10 – 12:30 p.m. ET | |
| Location: | New York, NY | |
| Presentation: | Amber Salzman, Ph.D., president and chief executive officer | |
| Event: | Barclays Gene Editing & Gene Therapy Summit | |
| Date: | November 30, 2017 | |
| Time: | 9:00 – 9:20 a.m. ET | |
| Location: | New York, NY | |
| Presentation: | Amber Salzman, Ph.D., president and chief executive officer | |
A live and replay audio webcast of the Piper Jaffray Healthcare Conference presentation will be available from Adverum’s website at http://investors.adverum.com.
About Adverum Biotechnologies, Inc.
Adverum is a leading gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.
Adverum Contact: Leone Patterson Chief Financial Officer 650-665-7222 [email protected]
